UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 35

Sortiert nach

Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients

Cancer biology & therapy, 2018-01, Vol.19 (10), p.879-886

2018

Link zum Volltext

Verfügbarkeit prüfen

Are All Patients Truly Hormone Receptor Negative?

Journal of clinical oncology, 2017-05, Vol.35 (14), p.1627-1627

Moscetti, Luca

2017

Link zum Volltext

Verfügbarkeit prüfen

TDM-1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e13010-e13010

2021

Link zum Volltext

Verfügbarkeit prüfen

Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e12516-e12516

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract P2-09-14: Characteristics of TNBC patients carrying other than BRCA gene mutations

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P2-P2-09-14

2022

Link zum Volltext

Verfügbarkeit prüfen

evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS1119-TPS1119

2023

Link zum Volltext

Verfügbarkeit prüfen

Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.1046-1046

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET)

Clinical cancer research, 2021-06, Vol.27 (12), p.3443-3455

2021

Link zum Volltext

Verfügbarkeit prüfen

A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study

Cancer biology & therapy, 2019-02, Vol.20 (2), p.192-200

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-19-43: Palbociclib-fulvestrant (PALBO-FUL) and everolimus -exemestane (EVE-EXE) for second line hormonal treatment (HT) of metastatic breast cancer (MBC) with lobular histology: A propensity score matched analysis

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P1-P1-19-43

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT2-01-07: evERA Breast Cancer: A phase III study of giredestrant (GDC-9545) + everolimus vs exemestane + everolimus in patients with estrogen receptor+, HER2– locally advanced or metastatic breast cancer

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.OT2-01-07-OT2-01-07

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of pertuzumab in combination with trastuzumab and a taxane in first-line treatment for metastatic breast cancer (MBC): A multicenter, retrospective, observational study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e12504-e12504

2017

Link zum Volltext

Verfügbarkeit prüfen

Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases : Survey by outcome research network for evaluation of treatment results in oncology

Cancer, 2007-01, Vol.109 (2), p.274-281

2007

Link zum Volltext

Verfügbarkeit prüfen

Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e11542-e11542

2015

Link zum Volltext

Verfügbarkeit prüfen

Quality of life (QoL) and symptoms evaluation in metastatic breast cancer (MBC) patients (pts) treated with eribulin: Preliminary results of a prospective observational study

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e12031-e12031

2013

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab maintenance (BM) in first line treatment for metastatic breast cancer (MBC): A multicenter retrospective observational study

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.549-549

2015

Link zum Volltext

Verfügbarkeit prüfen

Temozolomide (TMZ) maintenance in patients with primary brain cancer treated with postoperative TMZ plus radiotherapy (RT): A retrospective analysis

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e12514-e12514

2012

Link zum Volltext

Verfügbarkeit prüfen

Progression-free survival (PFS) with maintenance treatment with bevacizumab (B) in patients with responding mCRC after first-line chemotherapy (CT) plus B

Journal of clinical oncology, 2012-02, Vol.30 (4_suppl), p.612-612

2012

Link zum Volltext

Verfügbarkeit prüfen

The predictive value of clinical variables in patients affected with non-small-cell lung cancer (NSCLC) treated with pemetrexed (PEM) plus platinum-based regimen: A retrospective analysis

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e18065-e18065

2012

Link zum Volltext

Verfügbarkeit prüfen

Natural history of malignant bone disease in non-small cell lung cancer: Preliminary results of a multicenter bone metastasis survey

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e19084-e19084

2013

Link zum Volltext

Verfügbarkeit prüfen

Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e15615-e15615

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB-226: mTOR inhibition by Temsirolimus as second-line treatment for advanced RCC: The Medical optimization of Torisel® (MoTOR) phase II trial by the Italian Kidney Cancer Group (GIR)

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.LB-226-LB-226

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 35

Suche als RSS-Feed

Aktive Filter

KollektionPublisher website

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(34)
Berichte
(1)

Sprache

Englisch
(35)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(10)
Life Sciences & Biomedicine
(10)
Science & Technology
(10)
Female
(7)
Oncology
(7)
Breast Neoplasms - Drug Therapy
(5)
Middle Aged
(5)
Adult
(4)
Aged
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Retrospective Studies
(4)
Biological And Medical Sciences
(3)
Breast Neoplasms - Mortality
(3)
Breast Neoplasms - Pathology
(3)
Chemotherapy
(3)
Medical Sciences
(3)
Metastasis
(3)
Metastatic Breast Cancer
(3)
Trastuzumab
(3)
Tumors
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(16)
Cancer Research
(5)
Transfusion
(4)
Cancer Biology & Therapy
(3)
Cancer
(2)
Blood
(1)
Clinical Cancer Research
(1)
International Journal Of Medical Sciences
(1)
Journal Of Chemotherapy
(1)

4 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients

Are All Patients Truly Hormone Receptor Negative?

TDM-1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis

Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis

Abstract P2-09-14: Characteristics of TNBC patients carrying other than BRCA gene mutations

evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC)

Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials

Abstract P2-13-12: High CD36 expression predicts worse event free survival in HER2-positive breast cancer patients treated with neoadjuvant trastuzumab-based therapy: An exploratory analysis of the NeoALTTO study

Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET)

A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study

Abstract P1-19-43: Palbociclib-fulvestrant (PALBO-FUL) and everolimus -exemestane (EVE-EXE) for second line hormonal treatment (HT) of metastatic breast cancer (MBC) with lobular histology: A propensity score matched analysis

Abstract OT2-01-07: evERA Breast Cancer: A phase III study of giredestrant (GDC-9545) + everolimus vs exemestane + everolimus in patients with estrogen receptor+, HER2– locally advanced or metastatic breast cancer

Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab

Efficacy of pertuzumab in combination with trastuzumab and a taxane in first-line treatment for metastatic breast cancer (MBC): A multicenter, retrospective, observational study

Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E), or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer: The FATA-GIM3 trial

Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases : Survey by outcome research network for evaluation of treatment results in oncology

Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study

Quality of life (QoL) and symptoms evaluation in metastatic breast cancer (MBC) patients (pts) treated with eribulin: Preliminary results of a prospective observational study

Bevacizumab maintenance (BM) in first line treatment for metastatic breast cancer (MBC): A multicenter retrospective observational study

Temozolomide (TMZ) maintenance in patients with primary brain cancer treated with postoperative TMZ plus radiotherapy (RT): A retrospective analysis

Progression-free survival (PFS) with maintenance treatment with bevacizumab (B) in patients with responding mCRC after first-line chemotherapy (CT) plus B

The predictive value of clinical variables in patients affected with non-small-cell lung cancer (NSCLC) treated with pemetrexed (PEM) plus platinum-based regimen: A retrospective analysis

Natural history of malignant bone disease in non-small cell lung cancer: Preliminary results of a multicenter bone metastasis survey

Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer

Abstract LB-226: mTOR inhibition by Temsirolimus as second-line treatment for advanced RCC: The Medical optimization of Torisel® (MoTOR) phase II trial by the Italian Kidney Cancer Group (GIR)

Aktive Filter

Suchergebnisse filtern